Overview
Imbruvica (Ibrutinib) 140 mg Capsules are used in the treatment of various blood cancers, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia, and chronic graft-versus-host disease (GVHD). Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that works by blocking the BTK protein, which is involved in the survival and spread of cancer cells. By targeting this protein, Imbruvica helps in reducing the growth of malignant cells, improving outcomes for patients with these conditions.





